Picture of blood cells

Open Access research which pushes advances in bionanotechnology

Strathprints makes available scholarly Open Access content by researchers in the Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS) , based within the Faculty of Science.

SIPBS is a major research centre in Scotland focusing on 'new medicines', 'better medicines' and 'better use of medicines'. This includes the exploration of nanoparticles and nanomedicines within the wider research agenda of bionanotechnology, in which the tools of nanotechnology are applied to solve biological problems. At SIPBS multidisciplinary approaches are also pursued to improve bioscience understanding of novel therapeutic targets with the aim of developing therapeutic interventions and the investigation, development and manufacture of drug substances and products.

Explore the Open Access research of SIPBS. Or explore all of Strathclyde's Open Access research...

Re: High nevus counts confer a favorable prognosis in melanoma patients by S ribero and co-workers, published in the International Journal of Cancer, 2015 (online 21 march 2015)

Autier, Philippe and Funck-Brentano, Elisa and Aegerter, Philippe and Boniol, Mathieu and Saiag, Philippe (2015) Re: High nevus counts confer a favorable prognosis in melanoma patients by S ribero and co-workers, published in the International Journal of Cancer, 2015 (online 21 march 2015). International Journal of Cancer, 137 (12). pp. 3006-3007. ISSN 0020-7136

[img]
Preview
Text (Autier-etal-IJOC-2015-Re-High-nevus-counts-confer-a-favorable-prognosis-in-melanoma-patients-by-S-ribero-and-co-workers)
Autier_etal_IJOC_2015_Re_High_nevus_counts_confer_a_favorable_prognosis_in_melanoma_patients_by_S_ribero_and_co_workers.pdf
Accepted Author Manuscript

Download (83kB)| Preview

    Abstract

    Dear Sir, The study by S Ribero and co-workers is welcome because only few studies have examined the outcome of cutaneous melanoma patients according to host characteristics associated with greater risk to be diagnosed with this cancer.1 Number and size of nevi is the strongest risk factor for melanoma occurrence, and despite a lack of evidence, it is generally assumed that higher risk of melanoma occurrence would also mean a higher risk of melanoma death. Because of this assumption, subjects with high nevus count are recommended to have regular skin examinations so that detection of melanoma at an early stage may prevent the occurrence of late stage, potentially lethal melanoma. However, contrary to assumptions, the study of Ribero et al. rather suggests that a high nevus count could be associated with a lower risk to die from melanoma, and this lower risk was in a multivariate analysis independent of age, sex, anatomic location, tumour phenotype, and sentinel lymph node status. Ribero et al. concluded that in patients with an excessive number of nevi, melanoma would have a less aggressive biological behavior.